多药耐药革兰阴性杆菌管理的全球调查:高收入国家与其他地区的实践差异
该在线调查覆盖76个国家1320名医务人员,发现碳青霉烯耐药革兰阴性菌肺炎和菌血症的管理实践差异广泛,高收入国家与其他地区在首选药物上存在显著不同,且低收入和中等收入国家获取新型抗菌药物受限。
要点
- 碳青霉烯耐药革兰阴性菌感染管理实践全球差异大
- 高收入国家与其他地区首选药物显著不同
- 低收入和中等收入国家新型抗菌药物可及性受限
核心结论
- 碳青霉烯耐药革兰阴性菌肺炎和菌血症的管理实践差异广泛,低收入和中等收入国家新抗菌药物可及性受限。
研究设计与样本
- 通过国家学会和专业网络开展的在线调查,使用123项问卷,共1320名来自76个国家的医务人员完成调查。
主要发现
- 受访者主要实践领域为成人感染病(56.2%;739/1320),其次为临床微生物学(13.0%;171/1320)。
- 各区域在所有感染综合征中首选药物存在显著差异,例如碳青霉烯耐药肠杆菌目(CRE)KPC首选多黏菌素:高收入国家5/381 vs 其他地区24/390,P < .001。
- 抗生素可及性差异最大的是头孢地尔、头孢他啶-阿维巴坦、依拉环素、美罗培南-韦博巴坦和亚胺培南-西司他丁-瑞来巴坦。
临床怎么用
- 临床医生应意识到碳青霉烯耐药革兰阴性菌感染管理实践存在全球差异,尤其在药物选择和新药可及性方面。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant gram-negative bacterial (MDR GNB) infections are associated with high mortality. The evidence base for the management of these infections is weak. Major international bodies have recently offered guidance on managing these infections. Their impact on real-life practice is unknown. METHODS: We conducted an online survey utilizing a 123-item questionnaire among healthcare professionals managing patients with serious MDR GNB infections via national societies and professional networks. RESULTS: A total of 1320 respondents from 76 countries completed the survey. The primary area of practice was adult infectious diseases (56.2%; 739/1320), followed by clinical microbiology (13.0%; 171/1320). There were significant differences among preferred first-choice agents (assuming all drugs were available) across infection syndromes in all regions (eg, polymyxins as first choice for carbapenem-resistant Enterobacterales [CRE] KPC; 5/381 in high-income countries [HICs] vs 24/390 in the rest of the world; P < .001), but more pronounced in low- and middle-income countries (LMICs). The greatest disparities in antibiotic availability were seen with cefiderocol, ceftolozane-tazobactam, eravacycline, meropenem-vaborbactam, and imipenem-cilastatin-relebactam. CONCLUSIONS: Management practices for carbapenem-resistant gram-negative pneumonia and bacteremia vary widely, complicated by limited access to new antimicrobial agents in the LMICs. Evaluations of the potential impact of these new antimicrobial agents on the outcome of infections in LMICs are urgently needed.
引用
- Manesh A, Aslan AT, Mohan George M, et al. Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World. Clin Infect Dis. 2026. PMID: 42227055. doi:10.1093/cid/ciag025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。